In their final thoughts, the experts illustrate the overall effect of bempedoic acid for statin-intolerant patients with atherosclerotic cardiovascular disease.
Leslie Cho, M.D., FACC, FESC, FSCAI: When you talk to your patients, other clinicians, managed care professionals, and decision-makers, where do you think eventually this drug will come into play? Do you think this will be before PCSK9 or after, or if they refuse PCSK9? What do you think?
Seth S. Martin, M.D., M.H.S., FACC, FAHA, FASPC: It feels to me like it’s a consideration alongside PCSK9 and is on the same level because you have to factor in that oral versus injectable preference that patients have. It’s just a nice opportunity, as we have those discussions with patients in clinic to provide multiple options, which, by the way, is an incredibly wonderful thing to be able to do now, when in the past, all we had were statins and some older therapies. It’s really nice to have these options. It’s a fun discussion to have with patients. Here are the different options you have. I think it should probably be introduced pretty early in the discussion, especially because it also can be paired together with ezetimibe [Zetia], as we’ve talked about. I would be having it alongside the discussions for PCSK9 inhibitors.
Leslie Cho, M.D., FACC, FESC, FSCAI: Yeah. I agree with you. That’s a very nice way to think about it. With that, we are going to close our discussion on CLEAR Outcomes. I want to thank you for joining us today. And I want to thank Dr Seth Martin from Johns Hopkins Hospital [Baltimore, Maryland] for also providing a wonderful discussion.
Seth S. Martin, M.D., M.H.S., FACC, FAHA, FASPC: Thank you, Dr Cho.
Leslie Cho, M.D., FACC, FESC, FSCAI: Thank you.
Transcript edited for clarity.